CN1100534C - 2－(1h－4(5)－咪唑基环丙基衍生物及含该衍生物的药物组合物和其制备方法 - Google Patents

2－(1h－4(5)－咪唑基环丙基衍生物及含该衍生物的药物组合物和其制备方法 Download PDF

Info

Publication number
CN1100534C
CN1100534C CN96195925A CN96195925A CN1100534C CN 1100534 C CN1100534 C CN 1100534C CN 96195925 A CN96195925 A CN 96195925A CN 96195925 A CN96195925 A CN 96195925A CN 1100534 C CN1100534 C CN 1100534C
Authority
CN
China
Prior art keywords
imidazolyl
cyclopropanamide
triphenylmethyl
cyclopropyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96195925A
Other languages
English (en)
Chinese (zh)
Other versions
CN1192143A (zh
Inventor
J·G·菲利浦
C·E·特霍尔德
A·M·汉
S·L·雅特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gliatech Inc
Original Assignee
Gliatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliatech Inc filed Critical Gliatech Inc
Publication of CN1192143A publication Critical patent/CN1192143A/zh
Application granted granted Critical
Publication of CN1100534C publication Critical patent/CN1100534C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Photoreceptors In Electrophotography (AREA)
CN96195925A 1995-05-30 1996-05-29 2－(1h－4(5)－咪唑基环丙基衍生物及含该衍生物的药物组合物和其制备方法 Expired - Fee Related CN1100534C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/453,359 1995-05-30
US08/453,359 US5652258A (en) 1995-05-30 1995-05-30 2-(4-imidazoyl) cyclopropyl derivatives

Publications (2)

Publication Number Publication Date
CN1192143A CN1192143A (zh) 1998-09-02
CN1100534C true CN1100534C (zh) 2003-02-05

Family

ID=23800267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96195925A Expired - Fee Related CN1100534C (zh) 1995-05-30 1996-05-29 2－(1h－4(5)－咪唑基环丙基衍生物及含该衍生物的药物组合物和其制备方法

Country Status (17)

Country Link
US (2) US5652258A (cg-RX-API-DMAC7.html)
EP (1) EP0837679B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001503013A (cg-RX-API-DMAC7.html)
KR (1) KR19990022137A (cg-RX-API-DMAC7.html)
CN (1) CN1100534C (cg-RX-API-DMAC7.html)
AT (1) ATE207354T1 (cg-RX-API-DMAC7.html)
AU (1) AU713767B2 (cg-RX-API-DMAC7.html)
CA (1) CA2222101A1 (cg-RX-API-DMAC7.html)
DE (1) DE69616328T2 (cg-RX-API-DMAC7.html)
DK (1) DK0837679T3 (cg-RX-API-DMAC7.html)
ES (1) ES2163019T3 (cg-RX-API-DMAC7.html)
FI (1) FI974363A7 (cg-RX-API-DMAC7.html)
MX (1) MX9709211A (cg-RX-API-DMAC7.html)
NO (1) NO975484D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ308410A (cg-RX-API-DMAC7.html)
PT (1) PT837679E (cg-RX-API-DMAC7.html)
WO (1) WO1996038141A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
US6008240A (en) * 1997-12-15 1999-12-28 Gliatech, Inc. 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
EP1147092A1 (en) 1999-01-18 2001-10-24 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6114350A (en) * 1999-04-19 2000-09-05 Nen Life Science Products, Inc. Cyanine dyes and synthesis methods thereof
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
EP1313470A4 (en) 2000-08-17 2005-02-16 Gliatech Inc NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
JP2004506685A (ja) * 2000-08-21 2004-03-04 グリアテツク・インコーポレイテツド 食欲の制御と肥満の治療のためのヒスタミンｈ３受容体逆アゴニストの使用
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
BR0308118A (pt) * 2002-03-01 2005-01-11 Warner Lambert Co Método para o tratamento de osteoartrite
EP1720847A1 (en) * 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
EP1720861A2 (en) 2004-02-25 2006-11-15 Eli Lilly And Company Histamine h3 receptor antagonists, preparation and therapeutic uses
US7632857B2 (en) 2004-04-01 2009-12-15 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
US7696234B2 (en) 2004-06-02 2010-04-13 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
US7705025B2 (en) 2004-08-23 2010-04-27 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
ATE418553T1 (de) 2004-10-18 2009-01-15 Lilly Co Eli Histamin-h3-rezeptor inhibitoren, ihre herstellung und therapeutische anwendungen
CA2600757C (en) 2005-03-17 2014-02-18 Eli Lilly And Company Pyrrolidine derivatives as histamine h3 receptor antagonists
CN101151244B (zh) 2005-04-01 2014-09-03 伊莱利利公司 组胺h3受体活性剂、制备和治疗用途
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
CA2622597A1 (en) * 2005-09-15 2007-03-22 Banyu Pharmaceutical Co., Ltd. Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
AU2011244325B2 (en) 2010-04-19 2015-12-17 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
ME03085B (me) 2010-07-29 2019-01-20 Oryzon Genomics Sa Demetilaza inhibitori lsd1 zasnovani na arilciklopropilaminu i njihova medicinska primjena
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
KR102079406B1 (ko) 2011-10-20 2020-02-19 오리존 지노믹스 에스.에이. Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물
WO2013057320A1 (en) 2011-10-20 2013-04-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) * 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
WO1992015567A1 (en) * 1991-02-27 1992-09-17 Seed Capital Investment (Sci) B.V. Imidazole-derivatives having agonistic or antagonistic activity on the histamine h3-receptor
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent

Also Published As

Publication number Publication date
FI974363L (fi) 1997-11-28
EP0837679B1 (en) 2001-10-24
FI974363A0 (fi) 1997-11-28
WO1996038141A1 (en) 1996-12-05
NZ308410A (en) 2001-06-29
US5990317A (en) 1999-11-23
CA2222101A1 (en) 1996-12-05
ES2163019T3 (es) 2002-01-16
AU5804796A (en) 1996-12-18
EP0837679A1 (en) 1998-04-29
DE69616328D1 (de) 2001-11-29
MX9709211A (es) 1998-07-31
ATE207354T1 (de) 2001-11-15
US5652258A (en) 1997-07-29
JP2001503013A (ja) 2001-03-06
EP0837679A4 (en) 1999-03-03
FI974363A7 (fi) 1997-11-28
PT837679E (pt) 2002-03-28
KR19990022137A (ko) 1999-03-25
NO975484D0 (no) 1997-11-28
AU713767B2 (en) 1999-12-09
CN1192143A (zh) 1998-09-02
DE69616328T2 (de) 2002-07-04
DK0837679T3 (da) 2002-02-11

Similar Documents

Publication Publication Date Title
CN1100534C (zh) 2－(1h－4(5)－咪唑基环丙基衍生物及含该衍生物的药物组合物和其制备方法
CN1072220C (zh) 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
CN1037348C (zh) 取代的5－(2－((2－芳基－2－羟乙基)氨基)丙基)－1,3－苯并间二氧杂环戊烯的制备方法
CN1216864C (zh) 烟碱性受体激动剂的正调节剂
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1111529C (zh) 作为神经激肽拮抗剂的哌嗪子基衍生物
CN1060285A (zh) 含氮非芳香杂环的稠环类似物
CN1688544A (zh) 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
CN1211982A (zh) 托烷衍生物,其制备和应用
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1922161A (zh) 1－哌嗪－和1－高哌嗪－羧酸酯衍生物、制备和其治疗用途
CN1094723A (zh) 羧酰胺衍生物
CN1688548A (zh) 喹啉抗生素中间体的制备方法
CN1303364A (zh) 氨基环己基醚化合物和其用途
CN1064080A (zh) 肽类化合物、其制备方法及含有这类化合物的药物组合物
CN1118467C (zh) 1,3,8－三氮杂螺[4,5]癸－4－酮衍生物
CN1067889A (zh) 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法
CN1859914A (zh) 苯基吡咯烷醚速激肽受体拮抗剂
CN1309654A (zh) 联苯基衍生物
CN1022322C (zh) 稠合吡唑3-氧代-丙腈衍生物的制备方法
CN1127488C (zh) 具有生长激素释放特性的化合物
CN1794985A (zh) 氮杂双环衍生物作为毒蕈碱受体拮抗剂
CN1291186A (zh) 环酰胺化合物
CN1178923C (zh) 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用
CN1152006C (zh) 联苯基衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1052954

Country of ref document: HK